{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:10:24Z","timestamp":1785168624996,"version":"3.55.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T00:00:00Z","timestamp":1319587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terlipressin before transplantation, and this may affect the posttransplant outcomes. We examined a cohort of patients with access to liver transplantation from our previously published study of terlipressin plus albumin versus albumin alone in the treatment of HRS1. The purpose of this analysis was the quantification of the survival benefits of liver transplantation for patients with HRS1. Ninety-nine patients were randomized to terlipressin or placebo. Thirty-five patients (35%) received a liver transplant. Among those receiving terlipressin plus albumin, the 180-day survival rates were 100% for transplant patients and 34% for nontransplant patients; among those receiving only albumin, the rates were 94% for transplant patients and 17% for nontransplant patients. The survival rate was significantly better for those achieving a reversal of hepatorenal syndrome (HRS) versus those not achieving a reversal (47% versus 4%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), but it was significantly lower for the responders versus those undergoing liver transplantation (97%). We conclude that the use of terlipressin plus albumin has no significant impact on posttransplant survival. Liver transplantation offers a clear survival benefit to HRS1 patients regardless of the therapy that they receive or the success or failure of HRS reversal. The most likely benefit of terlipressin in patients undergoing liver transplantation for HRS1 is improved pretransplant renal function, and this should make the posttransplant management of this difficult group of patients easier. For patients not undergoing transplantation, HRS reversal with terlipressin and\/or albumin improves survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22395","type":"journal-article","created":{"date-parts":[[2011,8,11]],"date-time":"2011-08-11T14:39:07Z","timestamp":1313073547000},"page":"1328-1332","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":99,"title":["Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1"],"prefix":"10.1097","volume":"17","author":[{"given":"Thomas D.","family":"Boyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Regenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rossaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Appenrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"G\u00fclberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Bexon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Teuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20250124","doi-asserted-by":"crossref","first-page":"935946","DOI":"10.1016\/j.jhep.2007.02.001","article-title":"Advances in the pathogenesis and treatment of type1 and type2 hepatorenal syndrome.","volume":"46","author":"Arroyo","year":"2007","journal-title":"J Hepatol"},{"key":"R2-11-20250124","doi-asserted-by":"crossref","first-page":"12821289","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.","volume":"41","author":"Alessandria","year":"2005","journal-title":"Hepatology"},{"key":"R3-11-20250124","doi-asserted-by":"crossref","first-page":"229236","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"R4-11-20250124","doi-asserted-by":"crossref","first-page":"13601368","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"; for Terlipressin Study Group. A randomized, prospective, doubleblind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-11-20250124","first-page":"13521359","article-title":"; for TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"MartinLlahi","year":"2008","journal-title":"Gastroenterology"},{"key":"R6-11-20250124","doi-asserted-by":"crossref","first-page":"830835","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R7-11-20250124","doi-asserted-by":"crossref","first-page":"576584","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology"},{"key":"R8-11-20250124","first-page":"20642077","article-title":"Acute kidney injury in cirrhosis.","volume":"48","author":"GarciaTsao","year":"2008","journal-title":"Hepatology"},{"key":"R9-11-20250124","doi-asserted-by":"crossref","first-page":"307313","DOI":"10.1111\/j.1600-6143.2004.00703.x","article-title":"The survival benefit of liver transplantation.","volume":"5","author":"Merion","year":"2005","journal-title":"Am J Transplant"},{"key":"R10-11-20250124","doi-asserted-by":"crossref","first-page":"148156","DOI":"10.1016\/0016-5085(87)90327-1","article-title":"Effects of renal impairment on liver transplantation.","volume":"93","author":"Rimola","year":"1987","journal-title":"Gastroenterology"},{"key":"R11-11-20250124","doi-asserted-by":"crossref","first-page":"361365","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation.","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"R12-11-20250124","first-page":"11791185","article-title":"Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"R13-11-20250124","doi-asserted-by":"crossref","first-page":"159161","DOI":"10.1016\/j.jhep.2003.10.024","article-title":"The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation.","volume":"40","author":"Moreau","year":"2004","journal-title":"J Hepatol"},{"key":"R14-11-20250124","first-page":"164176","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"R15-11-20250124","doi-asserted-by":"crossref","first-page":"18191827","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome.","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"R16-11-20250124","doi-asserted-by":"crossref","first-page":"140146","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A casecontrol study.","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"R17-11-20250124","doi-asserted-by":"crossref","first-page":"15141519","DOI":"10.1097\/TP.0b013e3181a4430b","article-title":"Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience.","volume":"87","author":"Xu","year":"2009","journal-title":"Transplantation"},{"key":"R18-11-20250124","doi-asserted-by":"crossref","first-page":"428430","DOI":"10.1097\/00007890-199102000-00030","article-title":"Longterm survival and renal function following liver transplantation in patients with and without hepatorenal syndromeexperience in 300 patients.","volume":"51","author":"Gonwa","year":"1991","journal-title":"Transplantation"},{"key":"R19-11-20250124","doi-asserted-by":"crossref","first-page":"735741","DOI":"10.1001\/archsurg.141.8.735","article-title":"Longterm analysis of combined liver and kidney transplantation at a single center.","volume":"141","author":"Ruiz","year":"2006","journal-title":"Arch Surg"},{"key":"R20-11-20250124","doi-asserted-by":"crossref","first-page":"22432251","DOI":"10.1111\/j.1600-6143.2008.02416.x","article-title":"Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK).","volume":"8","author":"Eason","year":"2008","journal-title":"Am J Transplant"},{"key":"R21-11-20250124","doi-asserted-by":"crossref","first-page":"11421148","DOI":"10.1002\/lt.21821","article-title":"Renal outcomes after liver transplantation in the Model for EndStage Liver Disease era.","volume":"15","author":"Sharma","year":"2009","journal-title":"Liver Transpl"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22395","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201111000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:08:38Z","timestamp":1737738518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201111000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22395","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}